Paul Stoffels' retirement at the end of last year after nine years as head of R&D at Johnson & Johnson was short lived – he's just been named chef executive of Galapagos.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Jyseleca (filgotinib) 200mg tablets to treat ulcerative colitis (UC) in adults whose UC is moderately to severely acti
After 22 years at the helm of Belgian biotech Galapagos, chief executive Onno van de Stolpe has decided it is time to retire and hand the reins to new leadership.
Galapagos has had to send its SIK inhibitor programme back to the drawing board after its lead compound GLPG3970 has failed two of three clinical trials, adding to a string of disappointmen
Episode 35 of the pharmaphorum podcast hears from Michael Smyth about Galapagos UK and joining the company as medical director just as COVID-19 hit. With RNA-based technology hitti
